CAPR — Capricor Therapeutics Balance Sheet
0.000.00%
Last trade - 00:00- $1.75bn
- $1.65bn
Annual balance sheet for Capricor Therapeutics, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | 2025 December 31st | |
|---|---|---|---|---|---|
| Period Length: | — | — | — | — | — |
| Source: | 10-K | 10-K | 10-K | 10-K | |
| Standards: | USG | USG | USG | USG | — |
| Status: | Final | Final | Final | Final | fx Preliminary |
| Cash and Equivalents | |||||
| Short Term Investments | |||||
| Cash and Short Term Investments | 34.9 | 41.4 | 39.5 | 152 | — |
| Net Total Accounts Receivable | |||||
| Net Total Receivables | 0.392 | 0.548 | 10.4 | 10.4 | — |
| Prepaid Expenses | |||||
| Total Current Assets | 36.4 | 42.9 | 50.9 | 163 | — |
| Gross Property, Plant And Equipment | |||||
| Accumulated Depreciation | |||||
| Net Property, Plant And Equipment | 4.62 | 6.94 | 7.61 | 6.87 | — |
| Net Intangible Assets | |||||
| Other Long Term Assets | |||||
| Total Assets | 41.3 | 50.1 | 58.7 | 170 | — |
| Payable / Accrued | |||||
| Accrued Expenses | |||||
| Notes Payable / Short Term Debt | |||||
| Current Portion of Long Term Debt / Capital Leases | |||||
| Total Other Current Liabilities | |||||
| Total Current Liabilities | 4.13 | 23.6 | 31.3 | 21 | — |
| Long Term Debt | |||||
| Total Long Term Debt | |||||
| Total Debt | |||||
| Total Other Liabilities | |||||
| Total Liabilities | 9.96 | 38.3 | 36.1 | 25 | — |
| Non Redeemable Preferred Stock | |||||
| Common Stock | |||||
| Additional Paid In Capital | |||||
| Retained Earnings (Accumulated Deficit) | |||||
| Other Equity | |||||
| Total Equity | 31.4 | 11.8 | 22.6 | 145 | — |
| Total Liabilities & Shareholders' Equity | 41.3 | 50.1 | 58.7 | 170 | — |
| Total Common Shares Outstanding |